RVLP · Rvl Pharmaceuticals PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.26M | $8.83M | - | $10.02M | $8.45M | $21.44M | - | $2.20M | $11.51M | $23.88M |
| Cost of Revenue | $1.95M | $2.30M | - | $2.52M | $2.23M | $2.14M | - | $1.15M | $709.0K | $13.49M |
| Gross Profit | $6.31M | $6.53M | - | $7.50M | $6.22M | $19.30M | - | $1.05M | $10.80M | $10.39M |
| R&D | $547.0K | $626.0K | - | $1.04M | $1.18M | $862.0K | - | $1.38M | $2.05M | $3.31M |
| SG&A | $13.89M | $16.20M | - | $20.38M | $20.17M | $23.83M | - | $24.84M | $21.05M | $18.92M |
| Total Operating Expenses | $28.33M | $16.82M | - | $21.42M | $21.34M | $24.70M | - | $26.22M | $30.98M | $22.23M |
| D&A | - | $93.0K | - | - | - | $89.0K | - | - | - | $3.99M |
| Operating Income | ($22.02M) | ($10.29M) | - | ($13.92M) | ($15.12M) | ($5.40M) | - | ($25.17M) | ($20.18M) | ($6.21M) |
| Interest Expense | $13.0K | $26.0K | - | $1.13M | $978.0K | $985.0K | - | $735.0K | $494.0K | $2.96M |
| Income Tax | - | - | - | - | - | - | - | $324.0K | $94.0K | $533.0K |
| Net Income | ($23.89M) | ($11.61M) | - | ($14.45M) | ($12.11M) | ($6.82M) | - | ($17.86M) | ($17.73M) | ($9.61M) |
| EPS - Basic | ($0.24) | ($0.12) | - | ($0.16) | ($0.14) | ($0.15) | - | ($0.14) | ($0.28) | - |
| EPS - Diluted | ($0.24) | ($0.12) | - | ($0.16) | ($0.14) | ($0.08) | - | ($0.28) | ($0.28) | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.16M | $32.64M | $44.54M | $59.75M | $27.41M | $26.34M | $40.44M | $8.35M | $99.78M | $109.21M |
| Accounts Receivable | $1.00M | $9.0K | $947.0K | $1.37M | - | - | $2.13M | $4.19M | $645.0K | $22.59M |
| Inventory | $1.36M | $213.0K | $784.0K | $621.0K | $528.0K | $838.0K | $838.0K | $824.0K | $1.02M | $16.95M |
| Accounts Payable | $2.53M | $2.63M | $2.41M | $7.00M | $5.44M | $4.73M | $3.78M | $4.45M | $1.55M | $4.52M |
| Current Assets | $25.75M | $38.35M | $56.98M | $70.91M | $40.19M | $59.33M | $59.38M | $23.39M | $249.48M | $161.35M |
| Total Assets | $85.40M | $111.11M | $128.51M | $155.35M | $124.83M | $144.31M | $144.67M | $109.55M | $335.01M | $355.17M |
| Current Liabilities | $68.39M | $16.41M | $19.72M | $21.48M | $18.55M | $21.29M | $20.11M | $53.93M | $265.51M | $48.65M |
| Long-term Debt | $63.60M | $67.13M | $75.00M | $75.00M | $55.00M | $55.00M | $55.00M | $29.93M | $214.72M | $219.75M |
| Total Liabilities | $69.08M | $71.11M | $77.42M | $86.81M | $66.32M | $74.83M | $67.94M | $54.80M | $266.56M | $269.97M |
| Stockholders' Equity | $16.33M | $40.00M | $51.09M | $68.55M | $58.51M | $69.48M | $76.73M | $54.75M | $68.45M | $85.20M |
| Retained Earnings | ($604.72M) | ($580.83M) | ($569.22M) | ($550.90M) | ($536.46M) | ($524.35M) | ($517.53M) | ($497.81M) | ($479.95M) | ($462.22M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($5.82M) | - | - | - | ($13.28M) | - | - | - | ($11.49M) |
| Investing Cash Flow | - | ($1.23M) | - | - | - | $10.0K | - | - | - | $6.88M |
| Financing Cash Flow | - | ($4.86M) | - | - | - | ($837.0K) | - | - | - | ($236.0K) |
| CapEx | - | $1.30M | - | - | - | $27.0K | - | - | - | $422.0K |
| Free Cash Flow | - | ($7.12M) | - | - | - | ($13.30M) | - | - | - | ($11.91M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 76.4% | 74.0% | - | 74.8% | 73.6% | 90.0% | - | 47.8% | 93.8% | 43.5% |
| Operating margin | -266.7% | -116.5% | - | -138.9% | -179.0% | -25.2% | - | -1146.1% | -175.3% | -26.0% |
| EBITDA margin | - | -115.5% | - | - | - | -24.7% | - | - | - | -9.3% |
| Net margin | -289.3% | -131.5% | - | -144.1% | -143.3% | -31.8% | - | -813.3% | -154.0% | -40.3% |
| Free cash flow margin | - | -80.6% | - | - | - | -62.0% | - | - | - | -49.9% |
| FCF / Net income | - | 0.61 | - | - | - | 1.95 | - | - | - | 1.24 |
| R&D / Revenue | 6.6% | 7.1% | - | 10.4% | 13.9% | 4.0% | - | 62.7% | 17.8% | 13.9% |
| SG&A / Revenue | 168.2% | 183.4% | - | 203.3% | 238.7% | 111.1% | - | 1131.2% | 182.9% | 79.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -28.0% | -10.5% | - | -9.3% | -9.7% | -4.7% | - | -16.3% | -5.3% | -2.7% |
| Return on equity | -146.3% | -29.0% | - | -21.1% | -20.7% | -9.8% | - | -32.6% | -25.9% | -11.3% |
| Return on invested capital | - | - | - | - | - | - | - | -23.5% | -5.6% | -1.6% |
| Liquidity | ||||||||||
| Current ratio | 0.38 | 2.34 | 2.89 | 3.30 | 2.17 | 2.79 | 2.95 | 0.43 | 0.94 | 3.32 |
| Quick ratio | 0.36 | 2.32 | 2.85 | 3.27 | 2.14 | 2.75 | 2.91 | 0.42 | 0.94 | 2.97 |
| Cash ratio | 0.28 | 1.99 | 2.26 | 2.78 | 1.48 | 1.24 | 2.01 | 0.15 | 0.38 | 2.24 |
| Leverage | ||||||||||
| Debt / Equity | 3.90 | 1.68 | 1.47 | 1.09 | 0.94 | 0.79 | 0.72 | 0.55 | 3.14 | 2.58 |
| Debt / Assets | 0.74 | 0.60 | 0.58 | 0.48 | 0.44 | 0.38 | 0.38 | 0.27 | 0.64 | 0.62 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1693.9x | -395.8x | - | -12.3x | -15.5x | -5.5x | - | -34.2x | -40.8x | -2.1x |
| Equity multiplier | 5.23 | 2.78 | 2.52 | 2.27 | 2.13 | 2.08 | 1.89 | 2.00 | 4.89 | 4.17 |
| Liabilities / Assets | 0.81 | 0.64 | 0.60 | 0.56 | 0.53 | 0.52 | 0.47 | 0.50 | 0.80 | 0.76 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.08 | - | 0.06 | 0.07 | 0.15 | - | 0.02 | 0.03 | 0.07 |
| Inventory turnover | 1.44 | 10.79 | - | 4.07 | 4.22 | 2.56 | - | 1.39 | 0.70 | 0.80 |
| Days sales outstanding | 44d | 0d | - | 50d | - | - | - | 696d | 20d | 345d |
| Days inventory outstanding | 254d | 34d | - | 90d | 87d | 143d | - | 262d | 525d | 459d |
| Days payable outstanding | 475d | 418d | - | 1012d | 891d | 806d | - | 1416d | 797d | 122d |
| Cash conversion cycle | -176d | -383d | - | -873d | - | - | - | -457d | -252d | 682d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -2.2% | -58.8% | - | 356.4% | -26.6% | -10.2% | - | -96.2% | -69.3% | -50.9% |
| Revenue CAGR (3y) | -39.6% | -43.4% | - | -46.5% | -47.2% | -29.0% | - | -65.6% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 1.5% | -66.2% | - | 614.7% | -42.4% | 85.8% | - | -97.4% | -38.4% | -63.0% |
| Operating income growth (YoY) | -45.6% | -90.7% | - | 44.7% | 25.0% | 13.1% | - | -296.1% | -140.0% | - |
| Net income growth (YoY) | -97.3% | -70.2% | - | 19.1% | 31.7% | 29.0% | - | -106.9% | -36.4% | -211.8% |
| EPS growth (YoY) | -71.4% | -50.0% | - | 42.9% | 50.0% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 46.5% | - | - | - | -11.7% | - | - | - | -1075.5% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -72.1% | -42.4% | -33.4% | 25.2% | -14.5% | -18.4% | -18.2% | -63.7% | -47.7% | -40.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$35.01M totalLicense And Contract Revenue$10.00M · 28.6%
Royalty And Licensing Revenue$9.99M · 28.5%
Upneeq Product$7.51M · 21.5%
Product$7.51M · 21.5%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing RVL Pharmaceuticals plc against the 5 most active filers in the same SIC group.